Doxazosin Tablet
Product Images NDC 71610-160

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71610-160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 2 mg (71610 0153 60)

Label for Doxazosin USP 2 mg oral tablets, containing 90 tablets. The label includes storage instructions, manufacturing by Apotex Inc. in Toronto, Canada, and repackaging by Aphena Pharma Solutions in Cookeville, Tennessee. It also shows batch number, expiration date, lot number, and indicates prescription use only.*

FDA Label Image

Bottle Label 8 mg (71610 0160 16)

Label for Doxazosin 8 mg oral tablets, containing 6000 tablets. The label includes storage instructions to keep between 20-25 degrees Celsius, notes that the tablets are light-resistant and should be kept out of reach of children. Manufactured by Apotex Inc. in Toronto, Canada, and repackaged by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label also displays the NDC number 71610-0160-16 and states RX Only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Chemical structure of Doxazosin, a human prescription drug active ingredient, shown as a detailed molecular diagram with atoms and bonds representing the compound.*

FDA Label Image

Figure1.jpg (Figure1)

Two line graphs show clinical data comparing Doxazosin to placebo over 14 weeks. The first graph depicts mean change in total symptom score from baseline, with Doxazosin showing a greater decrease. The second graph presents mean increase in maximum urinary flow rate, with Doxazosin showing a higher increase versus placebo. Both include sample sizes and significance indicators.*

FDA Label Image

Table3.jpg (Table3)

A data table summarizing effectiveness data from placebo-controlled trials of Doxazosin on symptom score and maximum flow rate in patients. It compares mean baseline and mean change values for placebo and Doxazosin at different dosages across three studies, along with a bar graph visually representing maximum flow rate and symptom score changes for placebo, 4 mg, and 8 mg doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.